TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2901270
Drug: Pancuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.1 mg kg‐1
Study: 7387807
Drug: Suxamethonium 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 1.0 mg kg‐1 followed by pancuronium 0.05 mg kg‐1
Study: 29981569
Drug: Intravenous amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amino acid solution
Study: 29981569
Drug: Intravenous dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dextrose solution
Study: 17315084
Drug: Milk supplement
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk supplement
Study: 24653653
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors and lifestyle modification
Study: 19688297
Drug: Imatinib in
Normalized name: Product containing imatinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib in combination with hydroxyurea (HU)
Study: 19688297
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) monotherapy
Study: 18625672
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP) level > 3.0 mg/L
Study: 15645268
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (IVM) - 3 mg i.v. morphine after spinal anesthesia
Study: 15645268
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (ITM) - 0.3 mg morphine with bupivacaine during spinal anesthesia
Study: 15645268
Drug: Intra-articular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular morphine (IAM) - 3 mg intra-articular morphine diluted in 10 ml saline before surgery
Study: 15645268
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C) - no additional drugs
Study: 11788624
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg mifepristone daily for 120 days
Study: 11788624
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg mifepristone daily for 120 days
Study: 11788624
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg mifepristone daily for 120 days (Shanghai)
Study: 11788624
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg mifepristone daily for 120 days (Shanghai)
Study: 12895329
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of mifepristone
Study: 8192116
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ondansetron and dexamethasone
Study: 3245859
Drug: 0.1% betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% betamethasone 17‐valerate cream
Study: 1778534
Drug: 0.25% prednicarbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% prednicarbate cream
Study: 1678236
Drug: Vehicle of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of 0.25% prednicarbate cream
Study: 6124991
Drug: TEM 15
Normalized name: DENDROPANAX DENTIGER ROOT WITH STEM 15 g in 100 mL TOPICAL CREAM [CURICIN PFcream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEM 15 mg
Study: 6124991
Drug: TEM 30
Normalized name: TUR System 30"
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEM 30 mg
Study: 6124991
Drug: MPD +
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MPD + TEM 15 mg
Study: 6124991
Drug: MPD +
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MPD + TEM 30 mg
Study: 6124991
Drug: CAF +
Normalized name: Caffeine and Sodium Benzoate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAF + TEM 15 mg
Study: 6124991
Drug: CAF +
Normalized name: Caffeine and Sodium Benzoate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAF + TEM 30 mg
Study: 6124991
Drug: CAF (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF (150 mg)
Study: 6124991
Drug: MPD (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPD (10 mg)
Study: 20937606
Drug: telcagepant 300
Normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: telcagepant 300 mg
Study: 20078608
Drug: telcagepant 800
Normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: telcagepant 800 mg
Study: 17587399
Drug: 2 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg/day (maximum 200 mg/day) of oral diazoxide
Study: 16258098
Drug: Antibiotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics plus G-CSF (ciprofloxacin and roxithromycin with G-CSF on days 4 to 13)
Study: 16258098
Drug: Antibiotics alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics alone (ciprofloxacin and roxithromycin)
Study: 16258098
Drug: Antibiotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics plus G-CSF
Study: 12011969
Drug: HR 500
Normalized name: Glucophage XR 24 HR 500 MG Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR 500 mg tid (Group A)
Study: 12011969
Drug: HR 1
Normalized name: Wal-Fex 24 HR 180 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR 1 g tid (Group B)
Study: 12011969
Drug: HR 1
Normalized name: Wal-Fex 24 HR 180 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR 1 g/day (Group D)
Study: 27084825
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate (220 mg, 110 mg twice daily for 4 days)
Study: 24670356
Drug: CC/CT+TT (wild
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC/CT+TT (wild type GSTP1 exon 6)
Study: 21626817
Drug: Phenotropil, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenotropil, 400 mg/day for 1 year
Study: 16140624
Drug: Test substances
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test substances (glue, body wash solution, dryer sheet)
Study: 16140624
Drug: Body wash
Normalized name: Olay Body Wash
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Body wash solution
Study: 8712125
Drug: Aminophylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (400 mg, oral administration for 90 minutes)
Study: 8712125
Drug: Nitroglycerin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (0.3 mg, sublingual)
Study: 31730554
Drug: Initial prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial prescription of 30 hydrocodone/acetaminophen pills (5/325 mg)
Study: 31730554
Drug: Initial prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial prescription of 10 hydrocodone/acetaminophen pills (5/325 mg)
Study: 27101805
Drug: Tadalafil 20‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20‐mg (on‐demand)
Study: 27101805
Drug: Sildenafil 100‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100‐mg (on‐demand)
Study: 26226090
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBT) with routine primary care; 12 weekly 50-min sessions
Study: 8432466
Drug: Erythromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (200 mg)
Study: 15083940
Drug: Neostigmine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (2 mg)
Study: 11475343
Drug: 7.5% icodextrin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% icodextrin-containing solution
Study: 9727896
Drug: Hypocaloric diet
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric diet plus metformin
Study: 2153334
Drug: Acetate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetate infusion (2.5 mmol/min)
Study: 2153334
Drug: Acetate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetate infusion (2.5 mmol/min) with glucose (20 g/m2 body surface area)
Study: 2153334
Drug: Bicarbonate infusion
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate infusion (2.8 mmol/min)
Study: 273932
Drug: Mouthwash formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwash formulations (specific formulations not detailed)
Study: 31366875
Drug: β-CRX-rich orange
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-CRX-rich orange juice (125 mL, after breakfast)
Study: 31366875
Drug: Placebo (β-CRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (β-CRX removed from orange juice, 125 mL, after breakfast)
Study: 25765784
Drug: Four mini-implants
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four mini-implants (GI)
Study: 25765784
Drug: Two mini-implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two mini-implants (GII)
Study: 25765784
Drug: Two standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two standard implants (GIII)
Study: 19388860
Drug: Olfactory stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olfactory stimulation with cherry-flavored scent in oxygen (4 L/min)
Study: 30847444
Drug: Oral piracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral piracetam
Study: 9721974
Drug: Conventional intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional intensive care treatment
Study: 8306739
Drug: Artificial lung‐expanding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial lung‐expanding compound (ALEC, 3.2 g via bronchoscope)
Study: 23290818
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for persistent dementia cases
Study: 23290818
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for persistent non-cognitive psychiatric disorder cases
Study: 8262872
Drug: Imipenem/cilastatin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (500 + 500 mg qds)
Study: 8262872
Drug: Aztreonam (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam (600 tds) and Clindamycin (1000 mg tds)
Study: 4037642
Drug: Caudal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal morphine 10 mg in saline 25 ml injected into the caudal epidural space at the end of surgery
Study: 4037642
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine 10 mg on request in the postoperative period
Study: 4037642
Drug: Caudal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal morphine 10 mg
Study: 30673030
Drug: Needleless jet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needleless jet injection system
Study: 27276234
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (systolic blood pressure target of 110 to 139 mm Hg)
Study: 27276234
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (systolic blood pressure target of 140 to 179 mm Hg)
Study: 22753922
Drug: Motesanib 125
Normalized name: Motesanib
DrugBank: Motesanib (DB05575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motesanib 125 mg plus carboplatin/paclitaxel
Study: 20003585
Drug: Topical 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-fluorouracil 5 percent cream, three successive applications with two-week intervals
Study: 20003585
Drug: Local petroleum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local petroleum jelly cream packing
Study: 20003585
Drug: Topical 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-fluorouracil 5 percent cream
Study: 17068214
Drug: Caffeine capsules
Normalized name: Butalbital, Aspirin, and Caffeine Capsules
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine capsules (dose = 4 mg/kg)
Study: 9595967
Drug: Metrifonate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (100 to 180 mg loading dose for 2 weeks, followed by 30 to 60 mg maintenance dose for 24 weeks)
Study: 8572867
Drug: Antihypertensive drug
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drug treatment for 3 months
Study: 2705806
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (n = 17)
Study: 25534375
Drug: Anthracycline-plus-taxane combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-plus-taxane combination with carboplatin (PMCb)
Study: 25534375
Drug: Anthracycline-plus-taxane combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-plus-taxane combination (PM)
Study: 21878677
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (0.625 mg/d) plus medroxyprogesterone acetate (2.5 mg/d)
Study: 27370892
Drug: Betamethasone 8
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone 8 mg
Study: 12059822
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 2 ml (placebo)
Study: 11072160
Drug: Amifostine during
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amifostine during radiation therapy (RT)
Study: 3324039
Drug: Intralesional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional steroid injection (2.5 mg) and griseofulvin
Study: 15316334
Drug: peg-IFN alpha-2a
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peg-IFN alpha-2a 180 microg once weekly plus ribavirin 400 mg twice daily
Study: 15316334
Drug: IFN alpha-2a
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alpha-2a 3 million units three times weekly plus ribavirin 400 mg twice daily
Study: 18664620
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of pantoprazole (20 mg or 40 mg)
Study: 18664620
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous doses of pantoprazole (0.8 mg/kg or 1.6 mg/kg)
Study: 18664620
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of pantoprazole (oral and intravenous)
Study: 16650135
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 300 mg daily
Study: 9001830
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg suspension
Study: 9001830
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg capsule (laboratory batch)
Study: 9001830
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg capsule (production batch)
Study: 31613883
Drug: Community treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community treatment using ready-to-use therapeutic food
Study: 20663779
Drug: Oral screen
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral screen (OS) application
Study: 17978594
Drug: Nebivolol (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (2.5, 5, 10, 20, or 40 mg once daily)
Study: 17978594
Drug: Nebivolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (10 mg and higher)
Study: 14534925
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of regular-release (RR) and sustained-release (SR) levodopa/benserazide
Study: 11069460
Drug: Finasteride 1
Normalized name: finasteride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 1 mg daily for 48 weeks
Study: 1970584
Drug: SK&F 104353
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK&F 104353 (800 micrograms inhaled)
Study: 6379136
Drug: Immediate administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate administration of a three-dose course of intravenously administered indomethacin in addition to usual medical therapy (fluid restriction and use of diuretics or digitalis or both)
Study: 6379136
Drug: Usual medical
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual medical therapy alone initially, with indomethacin as the first and surgery as the final backup measure
Study: 6379136
Drug: Usual medical
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual medical therapy alone initially, with surgery alone as backup
Study: 6379136
Drug: Usual medical
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual medical therapy with surgery as backup
Study: 6379136
Drug: Indomethacin as
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin as part of initial treatment
Study: 23374677
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 0.5 mg
Study: 23374677
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 2 mg
Study: 17244900
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine infused intra‐articular at 4 mL/hour for 72 hours
Study: 17244900
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline infused intra‐articular at 4 mL/hour for 72 hours (placebo)
Study: 17244900
Drug: No intra‐articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intra‐articular infusion catheter (control)
Study: 8797186
Drug: Nortriptyline (NT)
DrugBank: Nortriptyline (DB00540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nortriptyline (NT) 75 mg daily for up to 7 weeks
Study: 8041232
Drug: Ethanol (0.85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.85 g/kg)
Study: 8041232
Drug: Cocaine HCl
Normalized name: cocaine HCl
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine HCl (1.25 and 1.9 mg/kg)
Study: 1640806
Drug: Ethanol (0.85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.85 g/kg) with Cocaine
Study: 6151505
Drug: Propranolol (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (maximum 170 mg)
Study: 6151505
Drug: Metoprolol (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (maximum 187.5 mg)
Study: 6151505
Drug: Propranolol (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (various doses: 10 mg, 17.5 mg, 45 mg)
Study: 6151505
Drug: Metoprolol (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (various doses: 37.5 mg, 187.5 mg)
Study: 6151505
Drug: Inhaled isoprenaline
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled isoprenaline
Study: 26847307
Drug: CC depth
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC depth of 6-7 cm (G 6-7)
Study: 26847307
Drug: CC depth
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC depth of 5-6 cm (G 5-6)
Study: 20084363
Drug: Routine follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine follow-up and monthly telephone contact
Study: 15911037
Drug: Psychopharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychopharmacological therapy
Study: 12790358
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of Tc-99m-HMPAO
Study: 12790358
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of Tc-99m-HMPAO
Study: 12790358
Drug: Tc-99m-HMPAO adherence
Normalized name: Technetium tc 99m HMPAO
DrugBank: Technetium Tc-99m exametazime (DB09163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tc-99m-HMPAO adherence to mucus after inhalation
Study: 10559508
Drug: HMG CoA
Normalized name: HMG CoA reductase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG CoA reductase inhibitor medication (statins)
Study: 1781468
Drug: Overall prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall prescription error rate
Study: 28294380
Drug: Intra-oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-oral placebo appliance
Study: 21102589
Drug: Figitumumab (F)
Normalized name: Stomodine F
DrugBank: Figitumumab (DB11685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Figitumumab (F) at doses of 10 or 20 mg/kg (PCF10, PCF20)
Study: 20212496
Drug: Taranabant 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taranabant 0.5 mg
Study: 20212496
Drug: Taranabant 1
Normalized name: Taranabant
DrugBank: Taranabant (DB06624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taranabant 1 mg
Study: 20212496
Drug: Taranabant 2
Normalized name: Taranabant
DrugBank: Taranabant (DB06624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taranabant 2 mg
Study: 12599994
Drug: Diet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet containing 60 g/day soy protein
Study: 12599994
Drug: Diet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet containing 30 g/day soy protein
Study: 12599994
Drug: Diet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet containing 45 g/day soy protein